Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia

IF 2.2 4区医学 Q3 ONCOLOGY Cancer Causes & Control Pub Date : 2024-09-10 DOI:10.1007/s10552-024-01912-1

Gilberto Barranco, Itzel Vidal, Dulce Gama, Carlos Martínez, Brenda Acosta, Christian Ramos, Emmanuel Martínez, Juan Zazueta, Irma Olarte, Adolfo Martínez, Eduardo Cervera, Iveth Mendoza, Diana Arcos, Judith Cruz

{"title":"Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia","authors":"Gilberto Barranco, Itzel Vidal, Dulce Gama, Carlos Martínez, Brenda Acosta, Christian Ramos, Emmanuel Martínez, Juan Zazueta, Irma Olarte, Adolfo Martínez, Eduardo Cervera, Iveth Mendoza, Diana Arcos, Judith Cruz","doi":"10.1007/s10552-024-01912-1","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This work aimed to evaluate the impact of a guaranteed access program to imatinib on the survival of patients with Chronic Myeloid Leukemia.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We carried out a retrospective, observational, and analytical study of the database of patients diagnosed with Chronic Myeloid Leukemia of the Instituto Nacional de Cancerología and the Hospital General de México Dr. Eduardo to assess overall survival based on guaranteed access or not to imatinib.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>With an average follow-up of 99 months, all patients’ estimated 20-year overall survival was 72% (95% CI, 76–67). A significant difference was found in the 20-year survival probability in favor of patients with guaranteed access 76% (95% CI, 81–71) vs. 61% (95% CI, 69–52) (<i>p</i> < 0.001), in addition to those in which they had better attachment 81.2% (95% CI, 85–76) vs. 44.9% (95% CI, 52–37) (<i>p</i> < 0.001).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>CML is the most frequent chronic leukemia in Mexico. It mainly affects the economically active population (mean age 40), and the prognosis in our country has improved, emulating developed countries; however, the results depend on access to treatment and proper monitoring.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":"6 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Causes & Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10552-024-01912-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This work aimed to evaluate the impact of a guaranteed access program to imatinib on the survival of patients with Chronic Myeloid Leukemia.

Methods

We carried out a retrospective, observational, and analytical study of the database of patients diagnosed with Chronic Myeloid Leukemia of the Instituto Nacional de Cancerología and the Hospital General de México Dr. Eduardo to assess overall survival based on guaranteed access or not to imatinib.

Results

With an average follow-up of 99 months, all patients’ estimated 20-year overall survival was 72% (95% CI, 76–67). A significant difference was found in the 20-year survival probability in favor of patients with guaranteed access 76% (95% CI, 81–71) vs. 61% (95% CI, 69–52) (p < 0.001), in addition to those in which they had better attachment 81.2% (95% CI, 85–76) vs. 44.9% (95% CI, 52–37) (p < 0.001).

Conclusion

CML is the most frequent chronic leukemia in Mexico. It mainly affects the economically active population (mean age 40), and the prognosis in our country has improved, emulating developed countries; however, the results depend on access to treatment and proper monitoring.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊马替尼保障使用计划对慢性髓性白血病患者生存期的影响

方法我们对墨西哥国家癌症研究所和墨西哥爱德华多博士总医院的慢性髓性白血病患者数据库进行了一项回顾性、观察性和分析性研究，以评估是否保证伊马替尼的使用对慢性髓性白血病患者总生存期的影响。结果平均随访99个月，所有患者的20年总生存率估计为72%（95% CI，76-67）。结果在平均 99 个月的随访中，所有患者的估计 20 年总生存率为 72%（95% CI，76-67），其中有保障获得伊马替尼的患者的 20 年生存率为 76%（95% CI，81-71），而无保障获得伊马替尼的患者的 20 年生存率为 61%（95% CI，69-52）（p < 0.001），此外，有保障获得伊马替尼的患者的 20 年生存率为 81.2%（95% CI，85-76），而无保障获得伊马替尼的患者的 20 年生存率为 44.9%（95% CI，52-37）（p < 0.001）。它主要影响从事经济活动的人群（平均年龄 40 岁），我国的预后有所改善，正在向发达国家看齐；然而，结果取决于能否获得治疗和适当的监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Causes & Control 医学-公共卫生、环境卫生与职业卫生

CiteScore

3.90

自引率

4.30%

发文量

130

审稿时长

6.6 months

期刊介绍： Cancer Causes & Control is an international refereed journal that both reports and stimulates new avenues of investigation into the causes, control, and subsequent prevention of cancer. By drawing together related information published currently in a diverse range of biological and medical journals, it has a multidisciplinary and multinational approach. The scope of the journal includes: variation in cancer distribution within and between populations; factors associated with cancer risk; preventive and therapeutic interventions on a population scale; economic, demographic, and health-policy implications of cancer; and related methodological issues. The emphasis is on speed of publication. The journal will normally publish within 30 to 60 days of acceptance of manuscripts. Cancer Causes & Control publishes Original Articles, Reviews, Commentaries, Opinions, Short Communications and Letters to the Editor which will have direct relevance to researchers and practitioners working in epidemiology, medical statistics, cancer biology, health education, medical economics and related fields. The journal also contains significant information for government agencies concerned with cancer research, control and policy.